The platform Cologuard® (https://www.cologuardtest.com/meet-cologuard) received premarket approval by FDA in 2014 and was developed for screening early CRC, targeting mainly β-actin, KRAS mutations, and aberrantly methylated BMP3 and NDRG4 [163]. Here, KRAS is linked to colorectal carcinoma.